Novel insights into the nervous system affected by prolonged hyperglycemia

J Mol Med (Berl). 2023 Aug;101(8):1015-1028. doi: 10.1007/s00109-023-02347-y. Epub 2023 Jul 18.

Abstract

Multiple molecular pathways including the receptor for advanced glycation end-products-diaphanous related formin 1 (RAGE-Diaph1) signaling are known to play a role in diabetic peripheral neuropathy (DPN). Evidence suggests that neuropathological alterations in type 1 diabetic spinal cord may occur at the same time as or following peripheral nerve abnormalities. We demonstrated that DPN was associated with perturbations of RAGE-Diaph1 signaling pathway in peripheral nerve accompanied by widespread spinal cord molecular changes. More than 500 differentially expressed genes (DEGs) belonging to multiple functional pathways were identified in diabetic spinal cord and of those the most enriched was RAGE-Diaph1 related PI3K-Akt pathway. Only seven of spinal cord DEGs overlapped with DEGs from type 1 diabetic sciatic nerve and only a single gene cathepsin E (CTSE) was common for both type 1 and type 2 diabetic mice. In silico analysis suggests that molecular changes in spinal cord may act synergistically with RAGE-Diaph1 signaling axis in the peripheral nerve. KEY MESSAGES: Molecular perturbations in spinal cord may be involved in the progression of diabetic peripheral neuropathy. Diabetic peripheral neuropathy was associated with perturbations of RAGE-Diaph1 signaling pathway in peripheral nerve accompanied by widespread spinal cord molecular changes. In silico analysis revealed that PI3K-Akt signaling axis related to RAGE-Diaph1 was the most enriched biological pathway in diabetic spinal cord. Cathepsin E may be the target molecular hub for intervention against diabetic peripheral neuropathy.

Keywords: Cytoskeleton; Diabetes; Inflammation; Neuropathy; Sciatic nerve; Spinal cord.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cathepsin E
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / genetics
  • Diabetic Neuropathies* / genetics
  • Diabetic Neuropathies* / metabolism
  • Hyperglycemia* / genetics
  • Hyperglycemia* / pathology
  • Mice
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Receptor for Advanced Glycation End Products / genetics
  • Receptor for Advanced Glycation End Products / metabolism
  • Sciatic Nerve / pathology

Substances

  • Receptor for Advanced Glycation End Products
  • Cathepsin E
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt